New vaccine combo aims to supercharge immune attack on breast cancer
Disease control
Terminated
This study tested whether adding a HER2-targeting vaccine (VRP-HER2) to the immunotherapy drug pembrolizumab could boost the immune system's attack on advanced HER2-positive breast cancer. Eight participants were randomly assigned to receive the vaccine alone, pembrolizumab alone…
Phase: PHASE2 • Sponsor: Herbert Lyerly • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC